GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Cyclically Adjusted PB Ratio

Agenus (FRA:AJ8) Cyclically Adjusted PB Ratio : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agenus Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Agenus's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Cyclically Adjusted PB Ratio Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agenus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agenus's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Agenus's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Cyclically Adjusted PB Ratio falls into.



Agenus Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Agenus's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Agenus's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-8.827/131.7762*131.7762
=-8.827

Current CPI (Mar. 2024) = 131.7762.

Agenus Quarterly Data

Book Value per Share CPI Adj_Book
201406 13.541 100.560 17.745
201409 12.100 100.428 15.877
201412 5.953 99.070 7.918
201503 12.068 99.621 15.963
201506 18.440 100.684 24.134
201509 16.205 100.392 21.271
201512 15.031 99.792 19.848
201603 9.227 100.470 12.102
201606 3.457 101.688 4.480
201609 -4.304 101.861 -5.568
201612 -8.449 101.863 -10.930
201703 1.687 102.862 2.161
201706 -3.124 103.349 -3.983
201709 -8.680 104.136 -10.984
201712 -12.598 104.011 -15.961
201803 -17.807 105.290 -22.287
201806 -17.352 106.317 -21.507
201809 -18.886 106.507 -23.367
201812 -25.267 105.998 -31.412
201903 -15.317 107.251 -18.820
201906 -20.275 108.070 -24.723
201909 -26.401 108.329 -32.115
201912 -29.433 108.420 -35.774
202003 -21.715 108.902 -26.276
202006 -22.651 108.767 -27.443
202009 -17.818 109.815 -21.381
202012 -17.076 109.897 -20.476
202103 -14.625 111.754 -17.245
202106 -18.211 114.631 -20.935
202109 2.875 115.734 3.274
202112 2.373 117.630 2.658
202203 1.070 121.301 1.162
202206 0.229 125.017 0.241
202209 -1.396 125.227 -1.469
202212 -3.786 125.222 -3.984
202303 -3.200 127.348 -3.311
202306 -4.681 128.729 -4.792
202309 -6.344 129.860 -6.438
202312 -7.456 129.419 -7.592
202403 -8.827 131.776 -8.827

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agenus  (FRA:AJ8) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Agenus Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Agenus's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (FRA:AJ8) Business Description

Industry
Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines